Mga Batayang Estadistika
| CIK | 75439 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Medite Cancer Diagnostics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| May 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) May 2, 2019 MEDITE CANCER DIAGNOSTICS, INC. |
|
| May 6, 2019 |
Exhibit 99.1 May 2nd, 2019 MEDITE CANCER DIAGNOSTICS, INC. W. Austin Lewis IV, Chairman of the Board 10524 Moss Park Road, Ste 204-357 Orlando, Florida, 32805 RESIGNATION FROM MY POSITION AS CEO AND BOARD MEMBER AT MEDITE CANCER DIAGNOSTICS Dear Austin Lewis: I hereby respectfully resign from my position as Chief Executive Officer and Member of the Board of Directors of Medite Cancer Diagnostics, |
|
| April 23, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) April 17, 2019 MEDITE CANCER DIAGNOSTICS, INC. |
|
| April 2, 2019 |
MDIT / Medite Cancer Diagnostics, Inc. 15-12G/A 15-12G/A 1 mdit1512ga.htm 15-12G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 Amendment No.1 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-00935 MEDITE Cancer Di |
|
| April 1, 2019 |
MDIT / Medite Cancer Diagnostics, Inc. OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| March 22, 2019 |
MDIT / Medite Cancer Diagnostics, Inc. FORM 15 15-12G 1 mditform15mar222019.htm FORM 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-00935 MEDITE Cancer Diagnostics |
|
| March 18, 2019 |
8-K 1 mdit8k15mar2019.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 15, 2019 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorp |
|
| February 28, 2019 |
MDIT / Medite Cancer Diagnostics, Inc. PRE 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☑ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d)(2)) ☐ Definitive Information Statement MEDITE CANCER DIAGNOSTICS, INC. (Name of Registr |
|
| January 3, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) December 27, 2018 MEDITE CANCER DIAGNOSTICS, INC. |
|
| December 6, 2018 |
Form of Third Amendment to Forbearance Agreement THIRD AMENDMENT TO FORBEARANCE AGREEMENT EXHIBIT 10.1 Form of Third Amendment to Forbearance Agreement THIRD AMENDMENT TO FORBEARANCE AGREEMENT This THIRD AMENDMENT TO FORBEARANCE AGREEMENT (this “Amendment”) is entered into as of November 30, 2018, by and among MEDITE Cancer Diagnostics, Inc., a Delaware corporation (“Borrower”), and GPB Debt Holdings II LLC, a Delaware limited liability company (“Lender”). Capitalized terms used but no |
|
| December 6, 2018 |
Resignation Letter of Stephen Von Rump EXHIBIT 99.1 Resignation Letter of Stephen Von Rump November 30, 2018 Austin Lewis Chairman of the Board MEDITE Cancer Diagnostics, Inc. Dear Austin, I respectfully submit my resignation as CSO of MEDITE Cancer Diagnostics, Inc., effective today. Regards, /s/ Stephen Von Rump |
|
| December 6, 2018 |
8-K 1 mdit8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) November 30, 2018 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporatio |
|
| November 14, 2018 |
MDIT / Medite Cancer Diagnostics, Inc. QUARTERLY REPORT (Quarterly Report) 10-Q 1 mdit10qsep302018.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from |
|
| November 7, 2018 |
RESIGNATION LETTER OF STEPHEN VON RUMP EXHIBIT 99.1 RESIGNATION LETTER OF STEPHEN VON RUMP October 30, 2018 Austin Lewis Chairman of the Board Medite Cancer Diagnostics, Inc. Dear Austin, I respectfully submit my resignations from the positions of CEO and Director of Medite Cancer Diagnostics, Inc., effective today. Regards, /s/Stephen Von Rump |
|
| November 7, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K First Amendment CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) October 30, 2018 MEDITE CANCER DIAGNOSTICS, INC. |
|
| November 2, 2018 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated November 2, 2018 with respect to the shares of Common Stock of MEDITE Cancer Diagnostics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)( |
|
| November 2, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 MEDITE Cancer Diagnostics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 23282B403 (CUSIP |
|
| October 31, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) October 30, 2018 MEDITE CANCER DIAGNOSTICS, INC. |
|
| October 31, 2018 |
RESIGNATION LETTER OF STEPHEN VON RUMP EXHIBIT 99.1 RESIGNATION LETTER OF STEPHEN VON RUMP October 30, 2018 Austin Lewis Chairman of the Board Medite Cancer Diagnostics, Inc. Dear Austin, I respectfully submit my resignations from the positions of CEO and Director of Medite Cancer Diagnostics, Inc., effective today. Regards, /s/Stephen Von Rump |
|
| October 16, 2018 |
Form of Securities Purchase Agreement SECURITIES PURCHASE AGREEMENT EXHIBIT 10.1 Form of Securities Purchase Agreement SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) is dated as of October , 2018, between MEDITE Cancer Diagnostics, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (including its su |
|
| October 16, 2018 |
Form of Security Agreement SECURITY AGREEMENT EXHIBIT 10.3 Form of Security Agreement SECURITY AGREEMENT THIS SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of , 2018, by and among MEDITE Cancer Diagnostics, Inc., a Delaware corporation (the “Company”, and together with each of the undersigned direct and indirect Subsidiaries from time to time and any other Person who |
|
| October 16, 2018 |
Form of Secured Convertible Promissory Note EXHIBIT 10.2 Form of Secured Convertible Promissory Note NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED O |
|
| October 16, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) October 11, 2018 MEDITE CANCER DIAGNOSTICS, INC. |
|
| October 1, 2018 |
Form of Gary Pickett Employment Agreement EMPLOYMENT AGREEMENT EXHIBIT 10.2 Form of Gary Pickett Employment Agreement EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”), effective as of the 25th day of September 2018 (“Effective Date”), is entered into by and between Medite Cancer Diagnostics, Inc., a Delaware corporation (the “Company”), and Gary Pickett (the “Employee”). WITNESSETH: WHEREAS, the Company is a corporation existing and authorized to |
|
| October 1, 2018 |
Form of Second Amendment to Forbearance Agreement Second AMENDMENT TO FORBEARANCE AGREEMENT EXHIBIT 10.1 Form of Second Amendment to Forbearance Agreement Second AMENDMENT TO FORBEARANCE AGREEMENT This SECOND AMENDMENT TO FORBEARANCE AGREEMENT (this “Amendment”) is entered into as of September 25, 2018, by and among MEDITE Cancer Diagnostics, Inc., a Delaware corporation (“Borrower”), and GPB Debt Holdings II LLC, a Delaware limited liability company (“Lender”). Capitalized terms used bu |
|
| October 1, 2018 |
Resignation Letter of Stephen Von Rump EXHIBIT 99.1 Resignation Letter of Stephen Von Rump September 25, 2018 Austin Lewis Chairman of the Board Medite Cancer Diagnostics, Inc. Dear Austin, I respectfully submit my resignation as Interim CFO of Medite Cancer Diagnostics, Inc., effective today. Regards, /s/ Stephen Von Rump |
|
| October 1, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 25, 2018 MEDITE CANCER DIAGNOSTICS, INC. |
|
| September 6, 2018 |
MDIT / Medite Cancer Diagnostics, Inc. DEFINITIVE INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d)(2)) ☑ Definitive Information Statement MEDITE CANCER DIAGNOSTICS, INC. (Name of Registr |
|
| August 27, 2018 |
MDIT / Medite Cancer Diagnostics, Inc. PRELIMINARY INFORMATION STATEMENT PRE 14C 1 mditpre14csep2018.htm PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☑ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-5(d)(2)) ☐ Definitive Info |
|
| August 10, 2018 |
MDIT / Medite Cancer Diagnostics, Inc. QUARTERLY REPORT (Quarterly Report) 10-Q 1 mdit10qjun302018.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| July 30, 2018 |
8-K 1 mdit8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) July 25, 2018 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 3 |
|
| July 18, 2018 |
8-K 1 mdit8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) July 12, 2018 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 3 |
|
| July 12, 2018 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) is dated as of June , 2018, between MEDITE Cancer Diagnostics, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (including its successors and permitted assigns, the “Purc |
|
| July 12, 2018 |
Form of Secured Convertible Promissory Note Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| July 12, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) June 28, 2018 MEDITE CANCER DIAGNOSTICS, INC. |
|
| July 12, 2018 |
Exhibit 10.3 SECURITY AGREEMENT THIS SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of June , 2018, by and among MEDITE Cancer Diagnostics, Inc., a Delaware corporation (the “Company”, and together with each of the undersigned direct and indirect Subsidiaries from time to time and any other Person who becomes a party to th |
|
| July 12, 2018 |
First Amendment to Forebearance Agreement Exhibit 10.4 FIRST AMENDMENT TO FORBEARANCE AGREEMENT This FIRST AMENDMENT TO FORBEARANCE AGREEMENT (this “Amendment”) is entered into as of June 29, 2018, by and among MEDITE Cancer Diagnostics, Inc., a Delaware corporation (“Borrower”), and GPB Debt Holdings II LLC, a Delaware limited liability company (“Lender”). Capitalized terms used but not otherwise defined herein shall have the respective |
|
| June 22, 2018 |
MDIT / Medite Cancer Diagnostics, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File number 000-00935 MEDITE CAN |
|
| May 17, 2018 |
MDIT / Medite Cancer Diagnostics, Inc. ANNUAL REPORT (Annual Report) 10-K 1 mdit10kdec312017.htm ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file n |
|
| May 14, 2018 |
MDIT / Medite Cancer Diagnostics, Inc. NT 10-Q OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| May 1, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) April 26, 2018 MEDITE CANCER DIAGNOSTICS, INC. |
|
| March 29, 2018 |
MDIT / Medite Cancer Diagnostics, Inc. NT 10-K NT 10-K 1 form12b25-03292018080332.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 333-143570 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ x ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N |
|
| March 5, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) February 27, 2018 MEDITE CANCER DIAGNOSTICS, INC. |
|
| February 28, 2018 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 28, 2018 with respect to the shares of Common Stock of MEDITE Cancer Diagnostics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) |
|
| February 28, 2018 |
MDIT / Medite Cancer Diagnostics, Inc. / Bigger Capital Fund L P Passive Investment SC 13G 1 sc13g10022med02282018.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 MEDITE Cancer Diagnostics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Secur |
|
| February 26, 2018 |
MDIT / Medite Cancer Diagnostics, Inc. CURRENT REPORT (Current Report) Untitled Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) February 20, 2018 MEDITE CANCER DIAGNOSTICS, INC. |
|
| February 20, 2018 |
8-K 1 mdit8kfeb132018.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) February 13, 2018 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Inc |
|
| February 12, 2018 |
Exhibit 10.2 Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EF |
|
| February 12, 2018 |
Exhibit 10.3 Exhibit 10.3 SECURITY AGREEMENT THIS SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this ?Agreement?) dated as of February , 2018, by and among MEDITE Cancer Diagnostics, Inc., a Delaware corporation (the ?Company?, and together with each of the undersigned direct and indirect Subsidiaries from time to time and any other Person who beco |
|
| February 12, 2018 |
GUARANTY OF OBLIGATIONS OF MEDITE CANCER DIAGNOSTICS, INC. Exhibit 10.4 Exhibit 10.4 GUARANTY OF OBLIGATIONS OF MEDITE CANCER DIAGNOSTICS, INC. This GUARANTY, dated as of February , 2018 (this ?Guaranty?), is made by each of the undersigned (each a ?Guarantor?, and collectively, the ?Guarantors?), in favor of GPB Debt Holdings II, LLC, a Delaware limited liability company, in its capacity as collateral agent (in such capacity, the ?Collateral Agent? as he |
|
| February 12, 2018 |
8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) February 6, 2018 MEDITE CANCER DIAGNOSTICS, INC. |
|
| February 12, 2018 |
Exhibit 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as amended, restated, supplemented or otherwise modified from time to time, this ?Agreement?) is dated as of February , 2018, between MEDITE Cancer Diagnostics, Inc., a Delaware corporation (the ?Company?), and the purchasers identified on the signature pages hereto (including its successors and permitted a |
|
| February 12, 2018 |
SUBORDINATION AND INTERCREDITOR AGREEMENT Exhibit 10.5 Exhibit 10.5 SUBORDINATION AND INTERCREDITOR AGREEMENT THIS SUBORDINATION AND INTERCREDITOR AGREEMENT (as amended, restated, supplemented or otherwise modified, this ?Agreement?) is entered into as of this February , 2018, by and among (i) GPB Debt Holdings II, LLC, a Delaware limited liability company, in its capacity as collateral agent for each of the investors listed on Schedule I |
|
| February 9, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 mdit8kfeb42018.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) February 5, 2018 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incor |
|
| February 9, 2018 |
Blueprint Exhibit 10.1 FORBEARANCE AGREEMENT This FORBEARANCE AGREEMENT (this ?Agreement?) is entered into as of February 5, 2018, by and among MEDITE Cancer Diagnostics, Inc., a Delaware corporation (?Borrower?), and GPB Debt Holdings II LLC, a Delaware limited liability company (?Lender?). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such |
|
| January 30, 2018 |
Dr. Augusto Ocana Resignation Letter Blueprint EXHIBIT 99.1 Dr. Augusto Ocana Resignation Letter January 23, 2018 Dear Austin and Colleagues: Please accept this as my formal resignation as Board Member of MEDITE Cancer Diagnostics, Inc., effective today, Tuesday, January 23, 2018. I wish the best for MEDITE and each of you. Sincerely, /s/Dr. Augusto Ocana |
|
| January 30, 2018 |
Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) January 23, 2018 MEDITE CANCER DIAGNOSTICS, INC. |
|
| January 17, 2018 |
MDIT / Medite Cancer Diagnostics, Inc. CURRENT REPORT (Current Report) Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) January 17, 2018 MEDITE CANCER DIAGNOSTICS, INC. |
|
| January 17, 2018 |
Untitled Document |
|
| January 17, 2018 |
Untitled Document |
|
| January 5, 2018 |
Ex 99.1 Exhibit 99.1 |
|
| January 5, 2018 |
Resignation Letter of Eric Goehausen Exhibit 99.2 Exhibit 99.2 Resignation Letter of Eric Goehausen January 2, 2018 Dear Austin and Stephen: Regrettably, I hereby tender my resignation from the Board of Directors of MEDITE Cancer Diagnostics. Sincerely, Eric /s/ Eric M. Goehausen |
|
| January 5, 2018 |
MDIT / Medite Cancer Diagnostics, Inc. CURRENT REPORT (Current Report) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) January 2, 2018 MEDITE CANCER DIAGNOSTICS, INC. |
|
| November 14, 2017 |
MDIT / Medite Cancer Diagnostics, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File number 000-00935 MEDITE |
|
| November 7, 2017 |
Exhibit 99.2 Exhibit 99.2 |
|
| November 7, 2017 |
Exhibit 99.1 Exhibit 99.1 MEDITE Cancer Diagnostics Reports Appointments of New Chairman of the Board and Chief Executive Officer Orlando, FL, November 7, 2017 - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT, the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and prec |
|
| November 7, 2017 |
8-K 1 mdit8knov52017.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) November 5, 2017 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incor |
|
| October 2, 2017 |
Ex 10-1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as amended, restated, supplemented or otherwise modified from time to time, this ?Agreement?) is dated as of September 25, 2017, between Medite Cancer Diagnostics, Inc., a Delaware corporation (the ?Company?), and the purchaser identified on the signature pages hereto (including its successors and permitted assi |
|
| October 2, 2017 |
13.25% SENIOR SECURED CONVERTIBLE NOTE Ex 10-2 Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTI |
|
| October 2, 2017 |
Ex 10-3 Exhibit 10.3 SECURITY AGREEMENT THIS SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of September 26, 2017, by and among Medite Cancer Diagnostics, Inc., a Delaware corporation (the “Company”, and together with each of the undersigned direct and indirect Subsidiaries from time to time and any other Person who become |
|
| October 2, 2017 |
Ex10-5 Exhibit 10.5 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (as it may be amended, restated, supplemented or otherwise modified from time to time, this ?Agreement?) is made and entered into as of September 26, 2017, by and among Medite Cancer Diagnostics, Inc., a Delaware corporation (the ?Company?), and the purchaser identified on the signature pages hereto (including its |
|
| October 2, 2017 |
COMMON STOCK PURCHASE WARRANT MEDITE CANCER DIAGNOSTICS, INC. Ex 10-4 Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIV |
|
| October 2, 2017 |
8-K 1 mdit8ksep262017.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) September 26, 2017 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of In |
|
| October 2, 2017 |
Ex10-6 Exhibit 10.6 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as amended, restated, supplemented or otherwise modified from time to time, this ?Agreement?) is dated as of September 26, 2017, between Medite Cancer Diagnostics, Inc., a Delaware corporation (the ?Company?), and the purchasers identified on the signature pages hereto (including its successors and permitted assi |
|
| September 6, 2017 |
Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) August 31, 2017 MEDITE CANCER DIAGNOSTICS, INC. |
|
| August 14, 2017 |
MDIT / Medite Cancer Diagnostics, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File number 000-00935 MEDITE CANC |
|
| August 11, 2017 |
Medite Cancer Diagnostics DEF 14C SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement MEDITE CANCER DIAGNOSTICS, INC. (Nam |
|
| August 1, 2017 |
Medite Cancer Diagnostics PRE 14C SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement MEDITE CANCER DIAGNOSTICS, INC. (Nam |
|
| July 12, 2017 |
Entry into a Material Definitive Agreement SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) July 10, 2017 MEDITE CANCER DIAGNOSTICS, INC. |
|
| June 6, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) May 31, 2017 MEDITE CANCER DIAGNOSTICS, INC. |
|
| May 15, 2017 |
FIRST AMENDMENT TO AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT SEC Connect EXHIBIT 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT THIS FIRST AMENDMENT TO AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT (this “Amendment”), dated as of May , 2017, by and among MEDITE Cancer Diagnostics, Inc., a Delaware corporation, with headquarters located at 4203 SW 34th Street, Orlando, Florida 32811 (the “Company”), and each buyer identified |
|
| May 15, 2017 |
Medite Cancer Diagnostics QUARTERLY REPORT (Quarterly Report) Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .. Commission File number 000-00935 |
|
| May 10, 2017 |
SEC Connect EXHIBIT 10.2 |
|
| May 10, 2017 |
MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations SEC Connect Exhibit 99.3 MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations Orlando, FL, May 10th, 2017 – MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) (the “Company”) specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces fur |
|
| May 10, 2017 |
SEC Connect EXHIBIT 10.1 |
|
| May 10, 2017 |
Resignation Letter of Michael Ott SEC Connect EXHIBIT 99.2 Resignation Letter of Michael Ott To: The Board of Directors MEDITE Cancer Diagnostics, Inc. Ladies and Gentlemen: I hereby resign my position as Chairman of the Board of MEDITE Cancer Diagnostics, Inc. (the “Company”), effective immediately. Further I hereby resign from my position as Managing Director of the Company’s wholly-owned German subsidiary, Medite GmbH, as well |
|
| May 10, 2017 |
8-K 1 mdit8kmay42017.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) May 4, 2017 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 0 |
|
| May 10, 2017 |
Resignation Letter of Michaela Ott SEC Connect EXHIBIT 99.1 Resignation Letter of Michaela Ott To: The Board of Directors MEDITE Cancer Diagnostics, Inc. Gentlemen: I regret to advise you that due to personal reasons, I hereby resign my position as Chief Operating Officer of MEDITE Cancer Diagnostics, Inc. (the “Company”), effective immediately. Further I hereby resign my position as Managing Director of the Company’s wholly-owned |
|
| May 1, 2017 |
Medite Cancer Diagnostics FORM 10-K (Annual Report) SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number MEDITE |
|
| April 27, 2017 |
MEDITE Cancer Diagnostics Appoints Susan Weisman as Chief Financial Officer SEC Connect Exhibit 99.1 MEDITE Cancer Diagnostics Appoints Susan Weisman as Chief Financial Officer Orlando, Fl., April 27, 2017 -MEDITE Cancer Diagnostics, Inc., (OTCQB: MDIT) (the “Company”) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, today an |
|
| April 27, 2017 |
8-K 1 mdit8kapr272017.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) April 24, 2017 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporatio |
|
| April 27, 2017 |
EXECUTIVE EMPLOYMENT AGREEMENT SEC Connect Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is entered into as of April 26th, 2017, by and between MEDITE Cancer Diagnostics, a corporation (the “Company”), and Susan Weisman (the “Executive” as “Chief Financial Officer”). Statement of Purpose WHERREAS the Company desires to employ Executive, and Executive desires to accept such em |
|
| April 14, 2017 |
Medite Cancer Diagnostics PRIMARY DOCUMENT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number MEDITE CANCER DIAG |
|
| April 14, 2017 |
Medite Cancer Diagnostics FORM 10-K (Annual Report) 10-K 1 mdit10kdec312016.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| April 4, 2017 |
SETTLEMENT AGREEMENT OF ACCRUED WAGES Blueprint EXHIBIT 10.1 SETTLEMENT AGREEMENT OF ACCRUED WAGES THIS SETTLEMENT AGREEMENT OF ACCRUED WAGES (this “Agreement”) is entered into as of the 31st day of March, 2017, by and between MEDITE Cancer Diagnostics, Inc. (the “Company”), a Delaware corporation having offices at 4203 SW 34th Street, Orlando, Florida 32811, and Richard Domanik, who resides at 30908 N. Leesley Court, Libertyville, Il |
|
| April 4, 2017 |
SETTLEMENT AGREEMENT OF ACCRUED WAGES Blueprint EXHIBIT 10.3 SETTLEMENT AGREEMENT OF ACCRUED WAGES THIS SETTLEMENT AGREEMENT OF ACCRUED WAGES (this “Agreement”) is entered into as of the 31st day of March, 2017, by and between MEDITE Cancer Diagnostics, Inc. (the “Company”), a Delaware corporation having offices at 4203 SW 34th Street, Orlando, Florida 32811, and Michael Jolley, who resides at 34469 N. Circle Drive, Round Lake, IL 600 |
|
| April 4, 2017 |
SETTLEMENT AGREEMENT OF ACCRUED WAGES Blueprint EXHIBIT 10.2 SETTLEMENT AGREEMENT OF ACCRUED WAGES THIS SETTLEMENT AGREEMENT OF ACCRUED WAGES (this ?Agreement?) is entered into as of the 31st day of March, 2017, by and between MEDITE Cancer Diagnostics, Inc. (the ?Company?), a Delaware corporation having offices at 4203 SW 34th Street, Orlando, Florida 32811, and Daniel Kusswurm, who resides at 1140 Appleton Lane, Geneva, IL 60134 (?E |
|
| April 4, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 31, 2017 MEDITE CANCER DIAGNOSTICS, INC. |
|
| March 30, 2017 |
OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| March 21, 2017 |
Medite Cancer Diagnostics DEFINITIVE 14C SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement MEDITE CANCER DIAGNOSTICS, INC. (Nam |
|
| March 10, 2017 |
Medite Cancer Diagnostics PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement MEDITE CANCER DIAGNOSTICS, INC. (Name of Registr |
|
| February 23, 2017 |
8-K 1 mdit8kfeb162017.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2017 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of |
|
| February 23, 2017 |
SEC Connect EXHIBIT 99.1 Press Release Orlando, FL., February 23, 2017 ? MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT, ?MEDITE? or the ?Company?) today announced that Eric M. Goehausen has been elected to MEDITE?s Board of Directors. Mr. Goehausen has been the managing member of New Harbor Merchant Partners, a private family investment office that invests in growth-oriented businesses and special |
|
| January 18, 2017 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) January 16, 2017 MEDITE CANCER DIAGNOSTICS, INC. |
|
| January 11, 2017 |
SEC Connect Exhibit 16.1 January 11, 2017 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for Medite Cancer Diagnostics, Inc. (the Company) and on April 12, 2016, we reported on the consolidated financial statements of the Company as of and for the year ended December 31, 2015. On January 5, 2017, we were d |
|
| January 11, 2017 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits 8-K 1 mdit8kjan112017.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2017 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporat |
|
| December 22, 2016 |
Medite Cancer Diagnostics PRIMARY DOCUMENT (Current Report/Significant Event) SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2016 MEDITE CANCER DIAGNOSTICS, INC. |
|
| December 22, 2016 |
EX-99.1 2 ex99-1.htm INVESTOR PRESENTATION Exhibit 99.1 |
|
| December 14, 2016 |
EX-99.1 2 ex99-1.htm PRESENTATION Exhibit 99.1 |
|
| December 14, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) December 13, 2016 MEDITE CANCER DIAGNOSTICS, INC. |
|
| December 7, 2016 |
Medite Cancer Diagnostics DEFINITIVE INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Revised Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement MEDI |
|
| November 22, 2016 |
Medite Cancer Diagnostics REVISED PRELIMINARY 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: [ ] [X] Preliminary Information Statement Revised Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statem |
|
| November 16, 2016 |
Medite Cancer Diagnostics PRE 14C PRE 14C 1 mditpre14cnov2016.htm PRE 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement MEDITE C |
|
| November 15, 2016 |
MEDITE CANCER DIAGNOSTICS, INC. - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 333-143570 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ x ] Form 10-Q [ ] Form 10-D |
|
| November 15, 2016 |
Medite Cancer Diagnostics 10-Q (Quarterly Report) SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File number 000-009 |
|
| November 14, 2016 |
Medite Cancer Diagnostics FORM 8-K (Current Report/Significant Event) mdit8knov122016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) November 12, 2016 MEDITE CANCER DIAGNOSTICS, INC. |
|
| November 8, 2016 |
Medite Cancer Diagnostics FORM 8-K (Current Report/Significant Event) Untitled Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) November 5, 2016 MEDITE CANCER DIAGNOSTICS, INC. |
|
| November 1, 2016 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is entered into as of October 31, 2016, by and between MEDITE Cancer Diagnostics, Inc., (the “Company”), and David Patterson (the “Executive” as “Chief Executive Officer”). Statement of Purpose WHEREAS the Company desires to employ Executive, and Executive desires to accept such employment, on the te |
|
| November 1, 2016 |
MEDITE Cancer Diagnostics, Inc. Announces Management Changes Blueprint Exhibit 99.1 MEDITE Cancer Diagnostics, Inc. Announces Management Changes Orlando, Fl., November 1, 2016 -MEDITE Cancer Diagnostics, Inc., (OTCQB:MDIT, the “Company”) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces the following ap |
|
| November 1, 2016 |
SEC Connect UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) October 26, 2016 MEDITE CANCER DIAGNOSTICS, INC. |
|
| September 7, 2016 |
Medite Cancer Diagnostics AMENDMENT NO. 2 TO FORM 10-K (Annual Report) medite10ka2dec312015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file |
|
| September 7, 2016 |
CORRESP 1 filename1.htm MEDITE Cancer Diagnostics, Inc. 4203 SW 34th Street Orlando, FL 32811, U.S.A. Phone +1 (407) 996 9630 Fax +1 (407) 996 9631 Toll Free No. 888 225 2950 [email protected] September 7, 2016 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Kate Tillan, Assistant Chief Accountant RE: |
|
| September 2, 2016 |
Medite Cancer Diagnostics AMENDMENT NO. 1 TO FORM 10-Q (Quarterly Report) mdit10qajun302016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commi |
|
| August 25, 2016 |
Medite Cancer Diagnostics QUARTERLY REPORT (Quarterly Report) mdit10qjun302016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File number 0 |
|
| August 25, 2016 |
Medite Cancer Diagnostics QUARTERLY REPORT (Quarterly Report) mdit10qjun302016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File number 0 |
|
| August 25, 2016 |
Medite Cancer Diagnostics AMENDMENT NO. 1 TO FORM 10-K (Annual Report) medite10kadec312015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file n |
|
| August 25, 2016 |
Medite Cancer Diagnostics AMENDMENT NO. 1 TO FORM 10-K (Annual Report) medite10kadec312015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file n |
|
| August 25, 2016 |
CORRESP 1 filename1.htm MEDITE Cancer Diagnostics, Inc. 4203 SW 34th Street Orlando, FL 32811, U.S.A. Phone +1 (407) 996 9630 Fax +1 (407) 996 9631 Toll Free No. 888 225 2950 [email protected] August 25, 2016 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Kate Tillan, Assistant Chief Accountant RE: M |
|
| August 15, 2016 |
MEDITE CANCER DIAGNOSTICS, INC. - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 333-143570 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ x ] Form 10-Q [ ] Form 10-D |
|
| May 27, 2016 |
Securities Purchase Agreement SECURITIES PURCHASE AGREEMENT ex10-1.htm EXHIBIT 10.1 Securities Purchase Agreement SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of May , 2016, by and among MEDITE Cancer Diagnostics, Inc., a Delaware corporation, with headquarters located at 4203 SW 34th Street, Orlando, Florida 32811 (the “Company”), and each of the purchasers set forth on the signature pages hereto (the “Buyers” a |
|
| May 27, 2016 |
Security Agreement SECURITY AGREEMENT ex10-3.htm EXHIBIT 10.3 Security Agreement SECURITY AGREEMENT THIS SECURITY AGREEMENT (this “Agreement”) is made as of May 25, 2016 (the “Funding Date”) by and among MEDITE Cancer Diagnostics, Inc. a Delaware corporation (the "Company" or “Debtor” or “Pledgor”) and the Purchasers Listed On Exhibit A (individually the "Secured Party" and collectively, the “Secured Parties” or the “Purchasers”) to t |
|
| May 27, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) May 25, 2016 MEDITE CANCER DIAGNOSTICS, INC. |
|
| May 27, 2016 |
ex10-4.htm Exhibit 10.4 Warrant No.AR- Issue Date: May , 2016 THIS WARRANT AND THE SHARES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. EXCEPT AS OTHERWISE SET FORTH HEREIN OR IN THAT CERTAIN SECURITIES PURCHASE AGREEMENT DATED AS OF MAY , 2016 (THE “SECURITIES PURCHASE AGREEMENT”), NEITHER THIS WARRANT NOR ANY OF SUCH SHARES MAY |
|
| May 27, 2016 |
ex10-2.htm EXHIBIT 10.2 Secured Promissory Note THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAW, AND IT MAY NOT BE SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT OR STATE LAW OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS; AND THE COMPANY MAY REQUIRE AN OPINION OF COUNSEL AS TO THE |
|
| May 13, 2016 |
Medite Cancer Diagnostics FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File number 000-00935 MEDITE CANC |
|
| April 12, 2016 |
Medite Cancer Diagnostics FORM 10-K (Annual Report) medite105dec312015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number MEDITE CANCER |
|
| March 30, 2016 |
OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response . |
|
| March 30, 2016 |
8-K 1 mdit8kmar292016.htm FORM 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2016 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporatio |
|
| February 17, 2016 |
medite8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) February 12, 2016 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-143570 36-42 |
|
| January 8, 2016 |
Medite Cancer Diagnostics DEFR14C DEFR14C 1 v428697defr14c.htm DEFR14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION Amendment No. 1 Information Statement Pursuant to Section 14 (c) of the Securities Exchange Act of 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5 (d)(2)) x Definitive Inf |
|
| January 7, 2016 |
exhibit10-3.htm Exhibit 10.3 Form of Security Agreement SECURITY AGREEMENT THIS SECURITY AGREEMENT (this “Agreement”) is made as of December [ ], 2015 (the “Funding Date”) by and among MEDITE Cancer Diagnostics, Inc. a Delaware corporation (the "Company" or “Debtor” or “Pledgor”) and the Purchasers Listed On Exhibit A (individually the "Secured Party" and collectively, the “Secured Parties” or the |
|
| January 7, 2016 |
Form of Convertible Promissory Note EX-10.2 3 exhibit10-2.htm FORM OF CONVERTIBLE PROMISSORY NOTE Exhibit 10.2 Form of Secured Promissory Note THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAW, AND IT MAY NOT BE SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT OR STATE LAW OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS; A |
|
| January 7, 2016 |
exhibit10-4.htm Exhibit 10.4 Form of Warrant No. Issue Date: , 2015 THIS WARRANT AND THE SHARES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. EXCEPT AS OTHERWISE SET FORTH HEREIN OR IN THAT CERTAIN SECURITIES PURCHASE AGREEMENT DATED AS OF , 2015 (THE “SECURITIES PURCHASE AGREEMENT”), NEITHER THIS WARRANT NOR ANY OF SUCH SHARES MA |
|
| January 7, 2016 |
exhibit10-1.htm EXHIBIT 10.1 Securities Purchase Agreement SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of December 31, 2015, by and among MEDITE Cancer Diagnostics, Inc., a Delaware corporation, with headquarters located at 4203 SW 34th Street, Orlando, Florida 32811 (the “Company”), and each of the purchasers set forth on the signature pages hereto (th |
|
| January 7, 2016 |
8-K 1 medite8k-16706.htm MEDITE CANCER DIAGNOSTICS, INC. FORM 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) December 31, 2015 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or O |
|
| December 21, 2015 |
Medite Cancer Diagnostics DEFINITIVE INFORMATION STATEMENT DEF 14C 1 v427462def14c.htm DEFINITIVE INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14 (c) of the Securities Exchange Act of 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5 (d)(2)) x Defini |
|
| December 10, 2015 |
Medite Cancer Diagnostics PRE 14C PRE 14C 1 v426713pre14c.htm PRE 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14 (c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5 (d)(2)) ¨ Definitive Information Statemen |
|
| September 9, 2015 |
EXHIBIT 99.1 Press Release Investment by UNIC Technologies CEO Dr. Zhongxi Zheng for 5.06% of MEDITE Cancer Diagnostics, Inc. Highlights Digital Cancer Diagnostic Strategy Orlando, FL., September 9, 2015 - MEDITE Cancer Diagnostics, Inc., (OTC/QB: MDIT) specializing in the development, manufacturing, and marketing of immuno-assays and premium medical devices for detection, risk assessment and diag |
|
| September 9, 2015 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits 8-K 1 v4198388k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) September 4, 2015 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-1 |
|
| August 27, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) August 27, 2015 MEDITE CANCER DIAGNOSTICS, INC. |
|
| August 27, 2015 |
EXHIBIT 99.1 Press Release MEDITE Cancer Diagnostics, Inc. Successfully obtained Mexican Tender for 31 Stainers and First Delivery of new Manual Microtome to China Orlando, FL., August 27, 2015 - MEDITE Cancer Diagnostics, Inc., (OTC/QB: MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnos |
|
| May 18, 2015 |
Medite Cancer Diagnostics NT 10-Q NT 10-Q 1 v411035nt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2015 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on |
|
| May 14, 2015 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K 1 v4107508k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) May 14, 2015 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-143570 |
|
| May 14, 2015 |
EXHIBIT 16.1 Auditor Letter May 12, 2015 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Medite Cancer Diagnostics, Inc. We have read the statements that we understand Medite Cancer Diagnostics Inc. will include under Item 4.01of the Form 8-K report it will file regarding the recent change in auditors. We agree with such statements made regarding our firm. We have |
|
| May 14, 2015 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) May 12, 2015 MEDITE CANCER DIAGNOSTICS, INC. |
|
| April 16, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 v4074748k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) April 15, 2015 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-1435 |
|
| April 16, 2015 |
MEDITE Cancer Diagnostics, Inc. Announces short Delay for 10k Filing of 2014 Financials EX-99.1 2 v407474ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 Press Release MEDITE Cancer Diagnostics, Inc. Announces short Delay for 10k Filing of 2014 Financials Orlando, FL, – April 16th, 2014 – MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT), specializing in the development, manufacturing and marketing of superior molecular biomarkers and premium medical devices and consumables for detection, risk asses |
|
| March 31, 2015 |
Medite Cancer Diagnostics FORM NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2014 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report o |
|
| February 24, 2015 |
MDIT / Medite Cancer Diagnostics, Inc. DEF 14C - - FORM DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement MEDITE CANCER DIAGNOSTICS, INC. (Name of Registr |
|
| January 28, 2015 |
MDIT / Medite Cancer Diagnostics, Inc. PRE 14C - - PRELIMINARY INFORMATION STATEMENT PRE 14C 1 v399689pre14c.htm PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: x Preliminary Information Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ¨ Definitive Informat |
|
| December 11, 2014 |
MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) becomes new name for CytoCore Inc. (OTCBB: CYOE) EXHIBIT 99.1 Press Release December 11, 2014 MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) becomes new name for CytoCore Inc. (OTCBB: CYOE) MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT), an Orlando, Florida based company, formerly known as CytoCore Inc. (OTCBB: CYOE), specializing in Anatomic Pathology and Cytology equipment, supplies and cancer markers used by medical laboratories for the diagnos |
|
| December 11, 2014 |
8-K 1 v3962838k.htm 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) December 11, 2014 MEDITE CANCER DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incor |
|
| November 17, 2014 |
MDIT / Medite Cancer Diagnostics, Inc. NT 10-Q - - FORM NT10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report |
|
| October 9, 2014 |
MDIT / Medite Cancer Diagnostics, Inc. DEF 14C - - DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement CYTOCORE, INC. (Name of Registrant as Specified |
|
| September 29, 2014 |
MDIT / Medite Cancer Diagnostics, Inc. PRE 14C - - PRE 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: x Preliminary Information Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ¨ Definitive Information Statement CYTOCORE, INC. (Name of Registrant as Specified |
|
| September 11, 2014 |
EXHIBIT 99.1 Shareholder Letter September 11, 2014 To Our Shareholders and Friends, As we shared with you several months ago, the first half of 2014 was a period of significant progress for the Company as we completed the merger with CytoCore and successfully integrated the two businesses. Today we are operating as one Company with clear objectives - grow the MEDITE business, guide the development |
|
| September 11, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v3888458k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) September 11, 2014 CYTOCORE, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 333-143570 36-42 |
|
| August 15, 2014 |
MDIT / Medite Cancer Diagnostics, Inc. NT 10-Q - - FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Fo |
|
| July 7, 2014 |
July 7, 2014 To Our Shareholders and Friends, Last month, Cytocore, Inc. (OTCBB: CYOE) filed financial statements of Medite Enterprise, Inc. for 2012, 2013 and first quarter 2014 prepared in accordance with US GAAP with the Securities & Exchange Commission. The filing represented a significant milestone for our company. Shortly, we expect to change the name of our company to Medite Holdings, Inc. |
|
| July 7, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) July 7, 2014 CYTOCORE, INC. |
|
| July 2, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) June 30, 2014 CYTOCORE, INC. |
|
| June 17, 2014 |
UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS OF CYTOCORE, INC. EX-99.3 4 v381421ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS OF CYTOCORE, INC. The pro forma condensed consolidated balance sheets reflects preliminary estimates and assumptions based on the information available at the time of preparation, including, but not limited to, for the pro forma balance sheet the following events that occurred subsequent to |
|
| June 17, 2014 |
MEDITE ENTERPRISES INC. AND SUBSIDIARIES INDEX TO FINANCIAL STATEMENTS EX-99.2 3 v381421ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 MEDITE ENTERPRISES INC. AND SUBSIDIARIES INDEX TO FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Balance Sheets F-2 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income F-3 Unaudited Condensed Consolidated Statements of Cash Flows F-4 Notes to Unaudited Condensed Consolidated Financial Statements F-5 F- |
|
| June 17, 2014 |
MEDITE ENTERPRISES INC. AND SUBSIDIARIES INDEX TO FINANCIAL STATEMENTS EX-99.1 2 v381421ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 MEDITE ENTERPRISES INC. AND SUBSIDIARIES INDEX TO FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets F-3 Consolidated Statements of Operations and Comprehensive Income F-4 Consolidated Statements of Cash Flows F-5 Consolidated Statements of Stockholders’ Equity F-6 Notes to Consolid |
|
| June 17, 2014 |
Financial Statements and Exhibits 8-K/A 1 v3814218ka.htm AMENDMENT TO FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): April 1, 2014 CYTOCORE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-00935 36-4296006 (State or |
|
| April 15, 2014 |
CUSIP NO. 23282B403 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of this Schedule 13D filed on April , 2014, with respect to the shares of Common Stock, $0.001 par value, of Cytocore, Inc. This Joint Filing Agreement shall be filed as an |
|
| April 15, 2014 |
MDIT / Medite Cancer Diagnostics, Inc. / Ott Michaela - FORM SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 CYTOCORE, INC. |
|
| April 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): April 1, 2014 CYTOCORE, INC. |
|
| April 7, 2014 |
AMENDMENT NO. 2 TO STOCK PURCHASE AGREEMENT EX-2.3 2 v374142ex2-3.htm EXHIBIT 2.3 AMENDMENT NO. 2 TO STOCK PURCHASE AGREEMENT THIS AMENDMENT NO. 2 TO STOCK PURCHASE AGREEMENT, dated as of April 1, 2014 (this “Amendment”), is entered into by and among CYTOCORE, INC., a Delaware corporation (the “Company”), MEDITE ENTERPRISES, INC., a Florida corporation (the “Holding Company”), MEDITE GMBH, a corporation organized under the laws of Germany a |
|
| April 1, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ¨Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on |
|
| March 17, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 v3718538k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): March 15, 2014 CYTOCORE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-00935 36-4296006 (State or other Jurisdiction of Incorporation or O |
|
| March 17, 2014 |
AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT, dated as of March 15, 2014 (this “Amendment”), is entered into by and among CYTOCORE, INC., a Delaware corporation (the “Company”), MEDITE ENTERPRISES, INC., a Florida corporation (the “Holding Company”), MEDITE GMBH, a corporation organized under the laws of Germany and wholly owned by the Holding Compan |
|
| January 23, 2014 |
1 OTC BB CYOE A New Global Market Force in Histology and Cytology Cancer Diagnostics 1 OTC BB CYOE A New Global Market Force in Histology and Cytology Cancer Diagnostics Forward Looking Statement This presentation includes forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended, regarding future operating performance, events, trends and plans . |
|
| January 23, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 23, 2014 CYTOCORE, INC. |
|
| January 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): January 11, 2014 CYTOCORE, INC. |
|
| January 14, 2014 |
CYTOCORE TO ACQUIRE MEDITE - Combination Creates Publicly Traded Global Market Force in Cytology and Histology – Orlando, FL & Chicago, IL – January 13, 2014 – MEDITE Group, a leading developer of innovative, high-quality equipment and supplies for the cancer diagnostic segments of histology, pathology and cytology headquartered in Orlando, Florida today announced that it has signed a definitive purchase agreement to be acquired by Chicago-based CytoCore, Inc. |
|
| January 14, 2014 |
STOCK PURCHASE AGREEMENT BY AND AMONG CYTOCORE, INC. MEDITE ENTERPRISES, INC. MEDITE GMBH MICHAEL OTT AND MICHAELA OTT Dated January 11, 2014 Table of Contents Exhibits Exhibit A Form of Release Exhibit B Form of Non-Competition Agreement Exhibit C Form of Legal Opinion of the Company Exhibit D Form of Legal Opinion of the Holding Company Exhibit 3.1.a Articles of Incorporation and Bylaws of Medit |
|
| September 11, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement CYTOCORE, INC. (Name of Registrant as Specified |
|
| August 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: x Preliminary Information Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ¨ Definitive Information Statement CYTOCORE, INC. (Name of Registrant as Specified |
|
| June 26, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement CYTOCORE, INC. (Name of Registrant as Specified |
|
| June 18, 2013 |
DEF 14C 1 v348046def14c.htm FORM DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement CYTOCOR |
|
| June 5, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT PURSUANT TO SECTION 14(c) OF THE SECURITIES EXCHANGE ACT OF 1934 Check the appropriate box: x Preliminary Information Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ¨ Definitive Information Statement CYTOCORE, INC. (Name of Registrant as Specified |
|
| May 24, 2013 |
May 20, 2013 Robert McCullough, Jr. 227 S. Ridgewood Rd. Kentfield, CA 94904 Robert: 1. Cytocore, Inc., a Delaware corporation (the “Company”), hereby agrees to issue to you (the “Stockholder”) 162,500,000 shares of the common stock, $0.001 par value per share (the “Shares”), of the Company in connection with the Stockholder’s capital contribution of the outstanding loan in the amount of $3.25 mil |
|
| May 24, 2013 |
8-K 1 v3461278k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): May 20, 2013 CYTOCORE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-00935 36-4296006 (State or other Jurisdiction of Incorporation o |
|
| November 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report |
|
| August 14, 2012 |
NT 10-Q 1 v321465nt10q.htm FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Repor |
|
| May 16, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on F |
|
| April 2, 2012 |
NT 10-K 1 v307857nt10k.htm FORM NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2011 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition R |
|
| March 7, 2012 |
8-K 1 v3049258k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): March 1, 2012 CYTOCORE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-00935 36-4296006 (State or other Jurisdiction of Incorporation or Organi |
|
| February 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): February 14, 2012 CYTOCORE, INC. |
